Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
BioXcel Therapeutics, Inc is a biotechnology business based in the US. BioXcel Therapeutics shares (BTAI) are listed on the NASDAQ and all prices are listed in US Dollars. BioXcel Therapeutics employs 31 staff and has a market cap (total outstanding shares value) of USD$1.2 billion.
|Latest market close||USD$53.88|
|52-week range||USD$3.76 - USD$71.5|
|50-day moving average||USD$46.0121|
|200-day moving average||USD$44.3467|
|Wall St. target price||USD$110.89|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.766|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||20.67%|
|1 month (2020-11-06)||1.53%|
|3 months (2020-09-04)||31.25%|
|6 months (2020-06-05)||12.91%|
|1 year (2019-12-05)||748.50%|
|2 years (2018-12-04)||1,008.64%|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-64.42%|
|Return on equity TTM||-136.53%|
|Market capitalisation||USD$1.2 billion|
TTM: trailing 12 months
There are currently 2.7 million BioXcel Therapeutics shares held short by investors – that's known as BioXcel Therapeutics's "short interest". This figure is 16.9% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting BioXcel Therapeutics shares can be evaluated.
BioXcel Therapeutics's "short interest ratio" (SIR) is the quantity of BioXcel Therapeutics shares currently shorted divided by the average quantity of BioXcel Therapeutics shares traded daily (recently around 515802.49042146). BioXcel Therapeutics's SIR currently stands at 5.22. In other words for every 100,000 BioXcel Therapeutics shares traded daily on the market, roughly 5220 shares are currently held short.
However BioXcel Therapeutics's short interest can also be evaluated against the total number of BioXcel Therapeutics shares, or, against the total number of tradable BioXcel Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioXcel Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 BioXcel Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.2127% of the tradable shares (for every 100,000 tradable BioXcel Therapeutics shares, roughly 213 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against BioXcel Therapeutics.
Find out more about how you can short BioXcel Therapeutics stock.
We're not expecting BioXcel Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, BioXcel Therapeutics's shares have ranged in value from as little as $3.76 up to $71.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BioXcel Therapeutics's is 1.6264. This would suggest that BioXcel Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.